nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.01.2012 | Original Paper

Condensed chromatin staining of CKAP2 as surrogate marker for mitotic figures

verfasst von: Han-Seong Kim, Yong-Bock Choi, Jung-Hwa Lee, Seong-Yeol Park, Hyun-Kyoung Kim, Jae-Soo Koh, Sang-Yeop Yi, Kyung-Tae Kim, Kyung-Uk Hong, Joobae Park, Chang-Dae Bae, Kyeong-Man Hong

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Proliferation activity has long been known to be one of the strongest prognostic factors in many different cancers. Nevertheless, microscopic evaluation of mitotic figures remains time-consuming and, furthermore, is relatively subjective. As the expression of cytoskeleton-associated protein 2 (CKAP2) is closely related to the mitotic phase, CKAP2 was evaluated as a surrogate mitotic figure (MF) marker.

Methods

A monoclonal antibody specific to human CKAP2 was produced, and immunohistochemistry was performed on normal tissue array sections and 30 breast cancer tissues.

Results

The expression of CKAP2 in the normal human tissues was limited to well-known cell proliferation zones. Strong, readily visible, condensed chromatin staining of CKAP2 was observed specifically in mitotic cells, and the number of these cells was tightly correlated with the MF count in breast cancer tissues (P < 0.001, ρ = 0.743), suggesting its usefulness as a surrogate marker for MF counting.

Conclusion

Immunohistochemical staining with CKAP2 monoclonal antibody can be considered to be a new, effective approach to the assessment of proliferation activity in cancer tissues.

Amadori D, Nanni O, Marangolo M, Pacini P, Ravaioli A, Rossi A, Gambi A, Catalano G, Perroni D, Scarpi E, Giunchi DC, Tienghi A, Becciolini A, Volpi A (2000) Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol 18(17):3125–3134PubMed

Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, Janssen EA (2005) Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23(25):5993–6001. doi:10.1200/JCO.2005.05.511 PubMedCrossRef

Baak JP, Gudlaugsson E, Skaland I, Guo LH, Klos J, Lende TH, Soiland H, Janssen EA, Zur Hausen A (2009) Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat 115(2):241–254. doi:10.1007/s10549-008-0126-y PubMedCrossRef

Bae CD, Sung YS, Jeon SM, Suh Y, Yang HK, Kim YI, Park KH, Choi J, Ahn G, Park J (2003) Up-regulation of cytoskeletal-associated protein 2 in primary human gastric adenocarcinomas. J Cancer Res Clin Oncol 129(11):621–630. doi:10.1007/s00432-003-0484-0 PubMedCrossRef

Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B, Terrier P, Bonvalot S, Le Cesne A, Vince-Ranchere D, Blay JY, Collin F, Guillou L, Leroux A, Coindre JM, Aurias A (2010) Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 16(7):781–787. doi:10.1038/nm.2174 PubMedCrossRef

Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D (2001) Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci USA 98(2):629–634. doi:10.1073/pnas.021386498 PubMedCrossRef

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921. doi:10.1038/nature03445 PubMedCrossRef

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134. doi:10.1056/NEJMoa0900212 PubMedCrossRef

Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guerry D (2005) Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 23(31):8048–8056. doi:10.1200/JCO.2005.02.0735 PubMedCrossRef

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312. doi:10.1200/JCO.2007.14.2364 PubMedCrossRef

Hong KU, Park YS, Seong YS, Kang D, Bae CD, Park J (2007) Functional importance of the anaphase-promoting complex-Cdh1-mediated degradation of TMAP/CKAP2 in regulation of spindle function and cytokinesis. Mol Cell Biol 27(10):3667–3681. doi:10.1128/MCB.01386-06 PubMedCrossRef

Hong KU, Choi YB, Lee JH, Kim HJ, Kwon HR, Seong YS, Kim HT, Park J, Bae CD, Hong KM (2008) Transient phosphorylation of tumor associated microtubule associated protein (TMAP)/cytoskeleton associated protein 2 (CKAP2) at Thr-596 during early phases of mitosis. Exp Mol Med 40(4):377–386PubMedCrossRef

Hong KU, Kim HJ, Bae CD, Park J (2009a) Characterization of mitosis-specific phosphorylation of tumor-associated microtubule-associated protein. Exp Mol Med 41(11):832–840. doi:10.3858/emm.2009.41.11.089 PubMedCrossRef

Hong KU, Kim HJ, Kim HS, Seong YS, Hong KM, Bae CD, Park J (2009b) Cdk1-cyclin B1-mediated phosphorylation of tumor-associated microtubule-associated protein/cytoskeleton-associated protein 2 in mitosis. J Biol Chem 284(24):16501–16512. doi:10.1074/jbc.M900257200 PubMedCrossRef

Hsu CY, Ho DM, Yang CF, Chiang H (2003) Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Mod Pathol 16:951–957PubMedCrossRef

Jeon SM, Choi B, Hong KU, Kim E, Seong YS, Bae CD, Park J (2006) A cytoskeleton-associated protein, TMAP/CKAP2, is involved in the proliferation of human foreskin fibroblasts. Biochem Biophys Res Commun 348(1):222–228. doi:10.1016/j.bbrc.2006.07.046 PubMedCrossRef

Jin Y, Murakumo Y, Ueno K, Hashimoto M, Watanabe T, Shimoyama Y, Ichihara M, Takahashi M (2004) Identification of a mouse cytoskeleton-associated protein, CKAP2, with microtubule-stabilizing properties. Cancer Sci 95(10):815–821PubMedCrossRef

Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13(2):R22. doi:10.1186/bcr2834 PubMedCrossRef

Kulkarni MB, Desai SB, Ajit D, Chinoy RF (2009) Utility of the thromboplastin-plasma cell-block technique for fine-needle aspiration and serous effusions. Diagn Cytopathol 37(2):86–90. doi:10.1002/dc.20963 PubMedCrossRef

Maouche-Chretien L, Deleu N, Badoual C, Fraissignes P, Berger R, Gaulard P, Romeo PH, Leroy-Viard K (1998) Identification of a novel cDNA, encoding a cytoskeletal associated protein, differentially expressed in diffuse large B cell lymphomas. Oncogene 17(10):1245–1251. doi:10.1038/sj.onc.1202048 PubMedCrossRef

Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A (2007) Targeting aurora kinases as therapy in multiple myeloma. Blood 109(9):3915–3921. doi:10.1182/blood-2006-07-037671 PubMedCrossRef

Valera V, Yokoyama N, Walter B, Okamoto H, Suda T, Hatakeyama K (2005) Clinical significance of Ki-67 proliferation index in disease progression and prognosis of patients with resected colorectal carcinoma. Br J Surg 92(8):1002–1007. doi:10.1002/bjs.4858 PubMedCrossRef

van Diest PJ, Baak JP, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, Kurver PH, Bellot SM, Fijnheer J, van Gorp LH, Kwee WS et al (1992) Reproducibility of mitosis counting in 2, 469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23(6):603–607PubMedCrossRef

Velders GA, Kluin-Nelemans JC, De Boer CJ, Hermans J, Noordijk EM, Schuuring E, Kramer MH, Van Deijk WA, Rahder JB, Kluin PM, Van Krieken JH (1996) Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 14(4):1269–1274PubMed

Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D (2002) Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13(6):1977–2000. doi:10.1091/mbc.02-02-0030 PubMedCrossRef

Titel: Condensed chromatin staining of CKAP2 as surrogate marker for mitotic figures
verfasst von: Han-Seong Kim
Yong-Bock Choi
Jung-Hwa Lee
Seong-Yeol Park
Hyun-Kyoung Kim
Jae-Soo Koh
Sang-Yeop Yi
Kyung-Tae Kim
Kyung-Uk Hong
Joobae Park
Chang-Dae Bae
Kyeong-Man Hong
Publikationsdatum: 01.01.2012
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2012
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-011-1053-6

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Condensed chromatin staining of CKAP2 as surrogate marker for mitotic figures

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience

Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome

Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation

Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin

The effects of vascular endothelial growth factor C knockdown in esophageal squamous cell carcinoma

The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie